Phosphagenics Initiates Clinical Trial In Type 1 Diabetes

Phosphagenics Limited has received ethics approval to commence treating patients with Type 1 diabetes in a Phase 2 clinical trial using its patented transdermal insulin delivery system, TPM/Insulin. The lead clinical investigators of the trial will be Dr. Michael D' Emden, Department of Endocrinology, Royal Brisbane and Women's Hospital, and William Hsu, who is an Assistant Investigator in the Section on Clinical Research at the Joslin Diabetes Centre and an Assistant Professor of Medicine at Harvard Medical School, Boston, MA.

Related Terms

Are you diabetic and looking for an easy way to lower your blood sugar levels after a meal? Researchers announced that a new potential blood sugar lowering drink for diabetics may just be that after dinner drink you need.

Urgo Medical findings support the use of sucrose octasulfate dressing as a local treatment for neuroischemic diabetic foot ulcers. This is the world's first effective dressing for healing diabetic wounds.

Defymed, a biotechnology company based in Strasbourg, plans to start clinical trials of an implantable insulin delivery device ExOlin, connected directly to the liver. The trials are set to start in 2018, with an aim of releasing the product to market in 2020.

According to a recent US study, published in the journal Diabetes Therapy, the ketogenic diet, which favors glucose-based fat, could reverse Type 2 Diabetes if it is accompanied by daily monitoring. Type 2 diabetes occurs in adults and affects mostly obese or overweight people.